
|Videos|July 15, 2020
The Evolving Role of Tucatinib in HER2-Positive Metastatic Breast Cancer
Author(s)Sara A. Hurvitz, MD
A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































